Basilea Pharmaceutica AG

SWX:BSLN Stock Report

Market Cap: CHF 493.4m

Basilea Pharmaceutica Future Growth

Future criteria checks 4/6

Basilea Pharmaceutica is forecast to grow earnings and revenue by 14.9% and 2.8% per annum respectively. EPS is expected to grow by 15.2% per annum. Return on equity is forecast to be 83.8% in 3 years.

Key information

14.9%

Earnings growth rate

15.2%

EPS growth rate

Biotechs earnings growth32.0%
Revenue growth rate2.8%
Future return on equity83.8%
Analyst coverage

Low

Last updated10 Jan 2025

Recent future growth updates

Recent updates

Shareholders May Be More Conservative With Basilea Pharmaceutica AG's (VTX:BSLN) CEO Compensation For Now

Apr 18
Shareholders May Be More Conservative With Basilea Pharmaceutica AG's (VTX:BSLN) CEO Compensation For Now

Does Basilea Pharmaceutica (VTX:BSLN) Deserve A Spot On Your Watchlist?

Sep 20
Does Basilea Pharmaceutica (VTX:BSLN) Deserve A Spot On Your Watchlist?

Robust Earnings May Not Tell The Whole Story For Basilea Pharmaceutica (VTX:BSLN)

Feb 17
Robust Earnings May Not Tell The Whole Story For Basilea Pharmaceutica (VTX:BSLN)

Revenue Downgrade: Here's What Analysts Forecast For Basilea Pharmaceutica AG (VTX:BSLN)

Jul 01
Revenue Downgrade: Here's What Analysts Forecast For Basilea Pharmaceutica AG (VTX:BSLN)

Analysts Expect Breakeven For Basilea Pharmaceutica AG (VTX:BSLN) Before Long

Mar 24
Analysts Expect Breakeven For Basilea Pharmaceutica AG (VTX:BSLN) Before Long

If You Had Bought Basilea Pharmaceutica's (VTX:BSLN) Shares Three Years Ago You Would Be Down 19%

Feb 18
If You Had Bought Basilea Pharmaceutica's (VTX:BSLN) Shares Three Years Ago You Would Be Down 19%

Earnings and Revenue Growth Forecasts

SWX:BSLN - Analysts future estimates and past financials data (CHF Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/20272317090822
12/31/20262497459583
12/31/20252224654495
12/31/20242035759575
6/30/2024149-1910N/A
3/31/202415351112N/A
12/31/2023158101314N/A
9/30/2023166332022N/A
6/30/2023175562729N/A
3/31/2023161341618N/A
12/31/20221481247N/A
9/30/20221506-21N/A
6/30/20221521-8-5N/A
3/31/2022150-3-20-18N/A
12/31/2021148-7-33-32N/A
9/30/2021130-26-41-40N/A
6/30/2021112-45-50-48N/A
3/31/2021120-30-53-51N/A
12/31/2020128-15-56-54N/A
9/30/2020134-6-55-53N/A
6/30/20201413-53-52N/A
3/31/2020137-10-58-58N/A
12/31/2019134-22-64-64N/A
9/30/2019135-23-64-64N/A
6/30/2019136-24-65-64N/A
3/31/2019134-28-72-72N/A
12/31/2018133-31-80-79N/A
9/30/2018124-26-43-42N/A
6/30/2018115-21-6-5N/A
3/31/2018108-20N/A7N/A
12/31/2017102-19N/A19N/A
9/30/201792-32N/A-19N/A
6/30/201782-44N/A-58N/A
3/31/201774-48N/A-66N/A
12/31/201666-51N/A-75N/A
9/30/201662-55N/A-89N/A
6/30/201658-59N/A-102N/A
3/31/201655-61N/A-85N/A
12/31/201553-62N/A-68N/A
9/30/201550-57N/A-57N/A
6/30/201547-52N/A-46N/A
3/31/201545-47N/A-59N/A
12/31/201442-42N/A-71N/A
9/30/201442-38N/A-71N/A
6/30/201441-35N/A-71N/A
3/31/201441-34N/A-65N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: BSLN is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (0.3%).

Earnings vs Market: BSLN is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: BSLN is expected to become profitable in the next 3 years.

Revenue vs Market: BSLN's revenue (2.8% per year) is forecast to grow slower than the Swiss market (4.4% per year).

High Growth Revenue: BSLN's revenue (2.8% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: BSLN's Return on Equity is forecast to be very high in 3 years time (83.8%).

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/02/06 04:19
End of Day Share Price 2025/02/06 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Basilea Pharmaceutica AG is covered by 25 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Leonildo DelgadoBaader Helvea Equity Research
Volker BosseBaader Helvea Equity Research
Markus MayerBaader Helvea Equity Research